Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Journal of the Korean Association of Maxillofacial Plastic and Reconstructive Surgeons ; : 250-256, 2004.
Article in Korean | WPRIM | ID: wpr-784556

ABSTRACT

40-years old) was 1.80+/-0.52mm and 1.51+/-0.58mm in younger age(<40-years old). The period between L2-and L3 showed significant changes in marginal bone oss(p<0.05). In conclusion, the marginal bone loss in L2-L3 period was most severe. Thus, the intensive care and follow-up in this period will be required to prevent excessive bone loss.


Subject(s)
Female , Humans , Male , Follow-Up Studies , Heart , Critical Care , Transplants
2.
Korean Journal of Medicine ; : 255-263, 2001.
Article in Korean | WPRIM | ID: wpr-153786

ABSTRACT

BACKGROUND: The long-term survival in patients with non-Hodgkin's lymphoma (NHL) after conventional chemotherapy is about 35% and the rest of the patients tend to have relapse. So, in relapsed or refractory NHL, the outcome of patients undergoing high-dose chemotherapy and autologous peripheral stem cell transplantation (APBSCT) was evaluated, and the main prognostic factors were determined. METHODS: 17 patients with relapsed or resistant NHL (5 complete response group, 7 partial response group, 4 primary refractory group, 1 resistant relapse) underwent BEAM (carmustine, etoposide, cytarabine, melphalan) chemotherapy and APBSCT between July 1997 and February 1999. RESULTS: The median follow-up duration was 17 months (range: 4-47). The response rate was 58.3% (complete response 33.3%, partial response 25.0%) in 12 patients in whom complete response group was not included. The 2-year, 3-year overall response rate were 41.2%, 27.5%, respectively. And 2-year progression free survival was 35.3%. The disease status before high-dose chemotherapy was the only significant prognostic factor in determining overall survival (univariate p=.024, multivariate p=.059) and progression free survival (univariate p=.013, multivariate p=.026). Patients with complete response to salvage regimen had better overall survival (p=.021) and progression free survival (p=.008) than patients with refractory response. WBC (> or = 1,000/uL) was recovered at the median 11 days (range; 8-24), and platelet (> or = 50,000/uL) was recovered at the median 18 days (range; 9-44). There was no treatment-related death and no grade 3 and 4 toxicity. Neutropenic infection was in 4 patients (1 Herpes zoster, 1 typhlitis, 1 perianal infection, 1 otitis externa). CONCLUSION: The pre-transplant disease status was the main prognostic factor. Patients with complete response to salvage regimen had the significant benefit in survival from high-dose chemotherapy and APBSCT, but patients with refractory or resistant relapsed NHL did not have any significant benefit.


Subject(s)
Humans , Blood Platelets , Cytarabine , Disease-Free Survival , Drug Therapy , Etoposide , Follow-Up Studies , Herpes Zoster , Lymphoma , Lymphoma, Non-Hodgkin , Otitis , Peripheral Blood Stem Cell Transplantation , Recurrence , Typhlitis
SELECTION OF CITATIONS
SEARCH DETAIL